SCHEMBL7158457

SCHEMBL7158457

CCCCCCCCCCCCCC(=O)O[C@H](CCCCCCCCCCC)CC(=O)N[C@H]1[C@@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@H](OP(=O)(O)O)[C@@H](CO)O[C@@H]1O

nearest known ligand 0.81

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ TLR4 O00206 19/20 0.81
▸ LY96 Q9Y6Y9 6/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7858795 1.00 TLR4 (0.81) TLR4LY96
SCHEMBL7866952 1.00 TLR4 (0.81) TLR4LY96
SCHEMBL7858800 1.00 TLR4 (0.81) TLR4LY96
SCHEMBL7858806 1.00 TLR4 (0.81) TLR4LY96
SCHEMBL7865447 1.00 TLR4 (0.81) TLR4LY96
SCHEMBL7865406 1.00 TLR4 (0.81) TLR4LY96
SCHEMBL7864286 1.00 TLR4 (0.81) TLR4LY96
SCHEMBL7864283 1.00 TLR4 (0.81) TLR4LY96
SCHEMBL7866945 1.00 TLR4 (0.81) TLR4LY96
SCHEMBL7865413 1.00 TLR4 (0.81) TLR4LY96

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030092643-A1 Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors CORIXA CORPORATION 2003-05-15 — — US disclosed
US-6303347-B1 VACCINES CORIXA CORPORATION 2001-10-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030092643-A1 Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors DNPEP, CD68, MGAT3 TLR4 70/4885LY96 87/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback